PMID- 37703851
OWN - NLM
STAT- Publisher
LR  - 20231122
IS  - 1423-0151 (Electronic)
IS  - 1011-7571 (Print)
IS  - 1011-7571 (Linking)
VI  - 32
IP  - 4-5
DP  - 2023 Sep 13
TI  - Thrombin Decrease in Thrombin Generation after Heparin Administration in a 
      Homozygous Type II Heparin Binding Site Antithrombin-Deficient Pregnant Woman.
PG  - 1
LID - 10.1159/000533801 [doi]
AB  - OBJECTIVES: There is a major problem in providing prophylactic treatment in 
      antithrombin (AT)-deficient pregnant women with a homozygous mutation of the 
      heparin binding site (HBS) and AT level of 17 %. The aim of the study was to 
      determine the effectiveness of heparin by monitoring changes in thrombin 
      generation (TG) in vitro so that pregnant women are not exposed to stress in 
      vivo. METHODS: We used the chromogenic method for determination of factor Xa 
      (FXa) inhibition for enoxaparine, nadroparine, dalteparine, fondaparinux and 
      unfractionated heparin (UFH) and the Thrombin Generation Assay (TGA). RESULTS: We 
      found that the degree of inhibition is very different when different heparins are 
      compared. Nadroparin reduces TG the most compared to low molecular weight 
      heparins (LMWH). CONCLUSION: Routine monitoring of anti FXa activity should be 
      supplemented with TG monitoring, where the effect of LMWH does not manifest 
      itself as this could help in estimating thrombophilic risk during pregnancy.
CI  - The Author(s). Published by S. Karger AG, Basel.
FAU - Malikova, Ivana
AU  - Malikova I
FAU - Husakova, Martina
AU  - Husakova M
FAU - Bilkova, Jana
AU  - Bilkova J
FAU - Brzezkova, Radka
AU  - Brzezkova R
FAU - Kvasnicka, Tomas
AU  - Kvasnicka T
LA  - eng
PT  - News
DEP - 20230913
PL  - Switzerland
TA  - Med Princ Pract
JT  - Medical principles and practice : international journal of the Kuwait University, 
      Health Science Centre
JID - 8901334
SB  - IM
PMC - PMC10659590
COIS- No conflicts of interest to disclose.
EDAT- 2023/09/14 00:42
MHDA- 2023/09/14 00:42
PMCR- 2023/11/01
CRDT- 2023/09/13 18:23
PHST- 2023/05/09 00:00 [received]
PHST- 2023/08/24 00:00 [accepted]
PHST- 2023/09/14 00:42 [medline]
PHST- 2023/09/14 00:42 [pubmed]
PHST- 2023/09/13 18:23 [entrez]
PHST- 2023/11/01 00:00 [pmc-release]
AID - 000533801 [pii]
AID - 533801 [pii]
AID - 10.1159/000533801 [doi]
PST - aheadofprint
SO  - Med Princ Pract. 2023 Sep 13;32(4-5):1. doi: 10.1159/000533801.